First Cloud-Based AI Endoscopy System for Colonoscopy Receives FDA ClearanceLeveraging the power of the cloud and AI to improve clinical outcomes
September 6, 2024
CENTER VALLEY, Pa. (Sept.5, 2024) – Odin Medical Ltd., an Olympus Corporation company, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the first cloud-based Artificial Intelligence (AI) technology designed to assist gastroenterologists in detecting suspected colorectal polyps during colonoscopy procedures, the CADDIE™ computer-aided detection (CADe) device.
In the constantly evolving, fast-paced world of AI, this innovative cloud-based technology supports doctors to improve the detection of the early signs of colorectal cancer using AI software that can be remotely updated. The flexibility, speed-to-innovation, and potential cost-savings of a cloud-based system is designed to help endoscopists provide a high level of care to patients.
“Together with Olympus, we are proud to bring this groundbreaking technology to the U.S. The cloud gives us the ability to keep hospitals up-to-date with advances in AI and gives peace of mind to doctors that they can easily access current technology for their patients,” said Peter Mountney, Ph.D., CEO of Odin Vision.
CADDIE™ device improves adenoma detection rate
A prospective, multi-center randomized controlled trial successfully demonstrated the efficacy and safety of the CADDIE device, underscoring its potential to enhance detection capabilities and patient care without increasing procedural risks or duration. The trial was conducted across eight medical centers in Europe.
“The trial shows that use of the CADDIE device improved the adenomas detected per colonoscopy, which is linked to cancer prevention.i The potential for this system to support more endoscopists in helping more patients is truly exciting,” said Professor Alessandro Repici, Chairman Department of Gastroenterology at Humanitas University & Humanitas Research Hospital, Italy, and principal investigator of the trial.
The CADDIE device works by analyzing colonoscopy video in real-time and using visual markers to alert the endoscopist to the potential presence of polyps. The endoscopist is responsible for reviewing the CADDIE device’s suspected polyp areas and confirming the presence or absence of a polyp based on their own medical judgment.
Olympus aims to reduce the societal burden of colorectal cancer
Supporting advancements in colorectal cancer screening and detection, Olympus aims to reduce the societal burden of lives lost to colorectal cancer, which claims more than 50M lives and is the second-leading cause of cancer deaths among men and women in the U.S. each year.ii Of concern is the rising incidence of colorectal cancer in people under 50, with forecasting models predicting that colorectal cancer will be the leading cause of cancer deaths in people under 50 by 2030.iii Early detection has never been more important. More than 90% of patients survive five years or more when the cancer is found at an early stage.iv
Improving the effectiveness of colonoscopy, considered the gold standard for colorectal screeningv, by strengthening clinical decision-making is one of the primary goals of the Olympus Intelligent Endoscopy Ecosystem, which will leverage the CADDIE device’s cloud connectivity and AI capabilities.
“As a global leader in endoscopy, it is our vision to make AI a key component of our digital transformation,” said Miquel Àngel García, Global Head of Endoscopy Solutions Ecosystem. “Odin’s success with this FDA clearance is an important step forward. A digitally transformed endoscopy ecosystem has the potential to support doctors and hospitals as they navigate global industry mega trends like cost pressures and staff shortages, in the context of an aging population. We are very excited about the huge opportunities for patients and healthcare systems that these advancements make possible.”
The CADDIE device is not intended to replace a full patient evaluation, nor is it intended to be relied upon to make a primary interpretation of endoscopic procedures, medical diagnosis, or recommendations of treatment/course of action for patients. The CADDIE device is limited to use with standard white-light endoscopy imaging only.
About Olympus
At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit olympus-global.com and follow our global X account: @Olympus_Corp.
About Odin Vision
Odin Vision, an Olympus company, is a pioneering Cloud AI endoscopy company. Our mission is to revolutionize endoscopy with the next generation of cloud AI-enabled applications. Odin Vision is a trading name of Odin Medical Ltd. For more information, visit odin-vision.com and follow our updates on the X account: @Odin_Vision.
i Schottinger JE, Jensen CD, Ghai NR, et al. Association of Physician Adenoma Detection Rates With Postcolonoscopy Colorectal Cancer. JAMA. 2022;327(21):2114–2122. doi:10.1001/jama.2022.6644
ii Key Statistics for Colorectal Cancer. Cancer.org. https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.htm. Revised Jan. 29, 2024.
iii Chun-Wei Pan C, Villaroman A, Cuartas MC, Gupta S. Rising trend of early-onset colorectal cancer in the US: Incidence and projections to 2030 [Abstract]. J. Clin. Oncol. 2024;42(16). doi.org/10.1200/JCO.2024.42.16_suppl.e15523
iv Survival Rates for Colorectal Cancer. Cancer.org. https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html. Revised Jan. 17, 2024.
v Colorectal Cancer: What You Should Know About Screening. FDA.gov. https://www.fda.gov/consumers/consumer-updates/colorectal-cancer-what-you-should-know-about-screening. Revised March 28, 2024.
* Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.
* The contents in this website including products availability, specifications or prices are the information as of the date of announcement and are subject to change without prior notice.
* Information is intended to be presented to the media, shareholders, investors, and other interested parties. Information about our medical products (including products currently under development) included in this website is not intended for advertising or medical advice.
* Olympus Corporation assumes no responsibility for any damage resulting from the use of this material.
* All company names and product names mentioned in this website are trademarks or registered trademarks of their respective companies. ® and TM marks are not specified in this website. All trademarks and registered trademarks are the property of their respective owners.